Anthony Benedetto, DO
Dermatology · Philadelphia, PANPI 1831154871
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Organogenesis Inc. at 58.5% of the total. Reporting peaked in 2022 at $29,339 and has fallen 53.3% since, to $13,694 in 2025. Among dermatology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 512 payments — averaging $189.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$57K
- Ipsen Biopharm Limited$15K
- AbbVie$13K
- Regeneron$5K
- Johnson & Johnson$2K
- Regeneron Healthcare Solutions, Inc.$564
- plus $5K from 34 others
Across 5 payments — averaging $2311.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$12K
What the payments were for
- Consulting fees$37,06538%
- Speaking & faculty fees$43,12544%
- Travel & lodging$5,9476%
- Food & beverage$10,32011%
- Education$4570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 92 | $56,686 |
| Ipsen Biopharm Limited | 2 | $15,200 |
| AbbVie | 106 | $12,954 |
| Regeneron | 4 | $5,225 |
| Johnson & Johnson | 94 | $1,743 |
| Regeneron Healthcare Solutions, Inc. | 23 | $564 |
| Pfizer | 25 | $521 |
| Novartis | 22 | $471 |
| UCB, Inc. | 17 | $391 |
| Incyte Corporation | 13 | $373 |
| Lilly USA, LLC | 16 | $343 |
| Merz North America, Inc. | 3 | $299 |
| Sanofi | 11 | $271 |
| Biofrontera Inc. | 14 | $242 |
| Strata Skin Sciences, Inc. | 15 | $177 |
| Amgen | 6 | $158 |
| Almirall LLC | 2 | $150 |
| Boehringer Ingelheim | 4 | $131 |
| Convatec Inc. | 4 | $127 |
| Revance Therapeutics, Inc. | 1 | $123 |
| LEO Pharma Inc. | 5 | $101 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $82 |
| Sun Pharmaceutical Industries Inc. | 4 | $72 |
| Kerecis Limited | 1 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $60 |
| VYNE Pharmaceuticals Inc. | 3 | $56 |
| Lumenis, Inc | 1 | $48 |
| Journey Medical Corporation | 2 | $40 |
| Mission Pharmacal Company | 2 | $29 |
| Triad Life Sciences Inc. | 1 | $29 |
| Misonix Inc | 2 | $25 |
| Organon | 2 | $25 |
| Bristol Myers Squibb | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Mimedx Group, Inc. | 1 | $16 |
| Dermira, Inc. | 1 | $14 |
| Conmed Corporation | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $14 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$96,914 in reported general payments places this provider in the 95th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 11 | $234,049 |
| TremfyaGuselkumab | 12 | $159,193 |
| OpzeluraRuxolitinib Phosphate | 13 | $25,536 |
| Clobetasol Propionate | 300 | $15,039 |
| Ciclopirox | 176 | $5,176 |
| CiclopiroxCiclopirox Olamine | 312 | $5,119 |
| Ketoconazole | 242 | $4,879 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 30 | $3,718 |
| Metronidazole | 26 | $1,871 |
| Cefadroxil | 242 | $1,828 |
| Imiquimod | 21 | $1,287 |
| Halobetasol Propionate | 36 | $1,252 |
| Clindamycin Phosphate | 33 | $1,205 |
| Gentamicin Sulfate | 32 | $1,144 |
| Pentoxifylline | 13 | $808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $1,743 | $159,19312 claims |
| Incyte CorporationOpzelura | $373 | $25,53613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 626 dermatology providers in Pennsylvania.
Other dermatology in Philadelphia
- Stephen HessPhiladelphia$1.7M
- Joel GelfandPhiladelphia$649K
- Victoria WerthPhiladelphia$547K
- Nicholas MollanazarPhiladelphia$369K
- Harold FarberPhiladelphia$284K
- Jules LipoffPhiladelphia$259K
- Susan TaylorPhiladelphia$207K
- Joy WanPhiladelphia$176K
- Harold MilsteinPhiladelphia$120K
- David MargolisPhiladelphia$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.